Investor Presentation First Nine Months of 2023

79 Investor presentation First nine months of 2023 Oral amycretin entered phase 1 in Q2 2022, combining protein. and peptide expertise with oral technology Amycretin is a GLP-1 and amylin receptor co-agonist intended for oral delivery Phase 1 single dose and multiple dose trial for oral amycretin in obesity initiated in 2022 GLP-1 receptor Novo NordiskⓇ People living with Multiple ascending dose cohorts overweight or obesity, and otherwise Single ascending dose cohorts healthy Trial objectives Amylin receptor • Assess the safety and tolerability of oral amycretin • Assess PK profile and explore PD effects Utilising the SNAC technology PK: Pharmacokinetics; PD: Pharmacodynamics Trial initiation • Phase 1 was initiated in Q2 2022

View entire presentation